EACS 2025: Hepatitis B Reactivation Rare After Switching from Tenofovir, European Studies Show
EACS 2025: Hepatitis B reactivation has long been a concern for people living with HIV who switch antiretroviral therapy (ART) regimens. Tenofovir, available as tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF), has proven effective not only in suppressing HIV but also in controlling hepatitis B virus (HBV). With the rising adoption of tenofovir-sparing ART…